Scienture Holdings, Inc.
No enriched coverage for $SCNX in the last 7 days.
No SEC Form 4 filings for $SCNX in the last 30 days.
Scienture Holdings (NASDAQ:SCNX) shares rose about 21% pre-market to $0.4046 after the company said it completed manufacturing of commercial launch inventory for REZENOPY (naloxone HCl) 10 mg nasal spray. Shipments to U.S. wholesalers are expected later this month, with retail availability in August. SCNX closed Thursday at $0.33.
Scienture Holdings (SCNX) said it completed manufacturing commercial launch inventory for REZENOPY naloxone nasal spray 10 mg and will start shipments to U.S. wholesalers in July, with broad availability expected in August. The company cited IQVIA data valuing the U.S. naloxone market at about $144 million annually and said payer access could cover over 100 million lives.
Scienture Holdings (NASDAQ: SCNX) said the U.S. Patent and Trademark Office granted U.S. Patent No. 12,622,903 B2 covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026 and expiring Feb. 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva. Scienture’s subsidiary has exclusive U.S. commercialization rights; REZENOPY™ was FDA-approved April 19, 2024. IQVIA data cited: ~$141M annual U.S. naloxone sales and 9.4M units (MAT Jan 2026).
Recent SCNX coverage spans financial news and market movers.
The pre-market jump is tied to a concrete commercialization milestone for REZENOPY, implying near-term distribution ramp risk-on.
Commercial inventory readiness and imminent wholesale shipments are a near-term execution catalyst for REZENOPY commercialization, supporting sentiment and potential demand visibility.
Patent grant extends IP protection and reinforces commercialization optionality for REZENOPY, potentially improving perceived product durability and risk profile.
SCIENTURE reported strong Q3 2025 financial results with significant revenue growth and increased gross profit, indicating positive operational momentum.
Scienture Holdings reported a substantial Q3 revenue increase from $65K to $590K and debt reduction, indicating improved financial health. The stock's sentiment is somewhat bullish with a sentiment score of 'somewhat-bullish'. The positive financial results may lead to upward price movement in the near term, especially if sustained.
alphai scores every news story that mentions SCNX with an AI model for sentiment and relevance, and aggregates insider trades from Scienture Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Scienture Holdings (NASDAQ:SCNX) shares rose about 21% pre-market to $0.4046 after the company said it completed manufacturing of commercial launch inventory for REZENOPY (naloxone HCl) 10 mg nasal spray. Shipments to U.S. wholesalers are expected later this month, with retail availability in August. SCNX closed Thursday at $0.33.
4 min readScienture Holdings (SCNX) said it completed manufacturing commercial launch inventory for REZENOPY naloxone nasal spray 10 mg and will start shipments to U.S. wholesalers in July, with broad availability expected in August. The company cited IQVIA data valuing the U.S. naloxone market at about $144 million annually and said payer access could cover over 100 million lives.
3 min readScienture Holdings (NASDAQ: SCNX) said the U.S. Patent and Trademark Office granted U.S. Patent No. 12,622,903 B2 covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026 and expiring Feb. 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva. Scienture’s subsidiary has exclusive U.S. commercialization rights; REZENOPY™ was FDA-approved April 19, 2024. IQVIA data cited: ~$141M annual U.S. naloxone sales and 9.4M units (MAT Jan 2026).
4 min readReports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to ...
3 min readOn Thursday, Scienture Holdings, Inc. ( NASDAQ:SCNX ) reported financial results for the third quarter. Net revenue increased from approximately $65 thousand to $590 thousand, while gross profit increased from roughly $4 thousand to $575 thousand.
2 min readScienture Holdings, Inc. ( NASDAQ:SCNX ) announced on Tuesday that Arbli ( losartan potassium ) Oral Suspension, 10 mg/mL, has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans.
3 min readMajor U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average up 0.3% at 46,734.61, the S&P 500 advancing nearly 0.6% to 6,738.44, and the Nasdaq climbing about 0.9% to 22,941.79. These are the top stocks that gained the attention of retail traders and investors through the ...
4 min readShares of Scienture Holdings, Inc. ( NASDAQ:SCNX ) are rising Thursday after the comprehensive pharmaceutical product company announced the start of commercial sales for Arbli. SCNX shares are powering higher on strong volume. Review the technical setup here.
2 min readCompany launches multi-channel promotional campaign to drive market adoption ...
3 min readScienture Holdings, Inc. ( NASDAQ:SCNX ) , a holding company for existing and planned pharmaceutical operating companies, announced Thursday that it started commercial sales and fulfillment of the first customer orders for Arbli ( losartan potassium ) Oral Suspension, 10 mg/mL.
2 min read
